Article
Polymerase Chain Reaction Adjustment in Antimalarial Trials: Molecular Malarkey?
26 May 2009
Abstract excerpt
Malaria drug trials use both clinical and microbiologic end points to establish efficacy. The recurrence of parasitemia after treatment is an indicator of treatment failure. The study by Faucher et al. [1] from Benin in this issue of the Journal demonstrates both substantial in vivo resistance to sulfadoxine‐pyrimethamine (SP) and good effectiveness of 2 new artemisinin combination therapies (ACTs):...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
